Chronic treatment with mood stabilizer lithium inhibits amphetamine-induced risk-taking manic-like behaviors

Neuroscience Letters

Volumn 603, Issue , 2015, Pages 84-88

  Zhou, Zhu ^a,b,c   Wang, Ying ^a,b   Tan, Hua ^a,b   Bharti, Veni ^a,b   Che, Yi ^c   Wang, Jun Feng ^a,b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Amphetamine; Elevated plus maze test; Lithium; Mania; Risk taking; Wire beam bridge test

Indexed keywords

AMPHETAMINE; LITHIUM; LITHIUM DERIVATIVE; TRANQUILIZER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; EXPERIMENTAL BEHAVIORAL TEST; HIGH RISK BEHAVIOR; LATENT PERIOD; LOCOMOTION; LONG TERM CARE; MALE; MANIA; NONHUMAN; PRIORITY JOURNAL; RAT; WIRE BEAM BRIDGE TEST; ANIMAL; BIPOLAR DISORDER; DRUG EFFECTS; MOTOR ACTIVITY; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; LITHIUM COMPOUNDS; MALE; MOTOR ACTIVITY; RATS, SPRAGUE-DAWLEY; RISK-TAKING;

EID: 84939186663     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.07.027     Document Type: Article

References (37)

1. Abulseoud O.A., Camsari U.M., Ruby C.L., Mohamed K., Abdel Gawad N.M., Kasasbeh A., Yüksel M.Y., Choi D.S. Lateral hypothalamic kindling induces manic-like behavior in rats: a novel animal model. Int. J. Bipolar Disord. 2014, 2:7.
2. Baptista T., Murzi E., Hernandez L., Burguera J.L., Burguera M. Mechanism of the sex-dependent effect of lithium on body weight in rats. Pharmacol. Biochem. Behav. 1991, 38:533-537.
3. Barney C.C., Kurylo D.M., Grobe J.L. Thermal dehydration-induced thirst in lithium-treated rats. Pharmacol. Biochem. Behav. 2003, 75:341-347.
4. Berk M., Berk L. Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. Ann. Clin. Psychiatry 2003, 15:217-224.
5. Bernstein I.L., Goehler L.E. Chronic lithium chloride infusions: conditioned suppression of food intake and preference. Behav. Neurosci. 1983, 97:290-298.
6. Bortolato M., Godar S.C., Davarian S., Chen K., Shih J.C. Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharmacology 2009, 34:2746-2757.
7. Chen H., Wu J., Zhang J., Hashimoto K. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Curr. Drug Abuse Rev. 2010, 3:222-238.
8. Curran G., Ravindran A. Lithium for bipolar disorder: a review of the recent literature. Expert Rev. Neurother. 2014, 14:1079-1098.
9. Correa C., Amboni G., Assis L.C., Martins M.R., Kapczinski F., Streck E.L., Quevado J. Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:887-891.
10. Davis J.F., Krause E.G., Melhorn S.J., Sakai R.R., Benoit S.C. Dominant rats are natural risk takers and display increased motivation for food reward. Neuroscience 2009, 162:23-30.
11. Dencker D., Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav. Brain Res. 2010, 207:78-83.
12. Eckel L.A., Ossenkopp K.P. Novel diet consumption and body weight gain are reduced in rats chronically infused with lithium chloride: mediation by the chemosensitive area postrema. Brain Res. Bull. 1993, 31:613-619.
13. Einat H., Manji H.K., Gould T.D., Du J., Chen G. Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect. 2003, 16:453-463.
14. Einat H., Yuan P., Szabo S.T., Dogra S., Manji H.K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007, 55:123-131.
15. Reddy L.F., Lee J., Davis M.C., Altshuler L., Glahn D.C., Miklowitz D.J., Green M.F. Impulsivity and risk taking in bipolar disorder and schizophrenia. Neuropsychopharmacology 2014, 39:456-463.
16. Flaisher-Grinberg S., Overgaard S., Einat H. Attenuation of high sweet solution preference by mood stabilizers: a possible mouse model for the increased reward-seeking domain of mania. J. Neurosci. Methods 2009, 15:44-50.
17. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiatry Neurosci. 2006, 31:326-332.
18. Gessa G.L., Pani L., Serra G., Fratta W. Animal models of mania. Depression and Mania: from Neurobiology to Treatment 1995, 49:43-66. Raven Press, New York.
19. Jukic M.M., Carrillo-Roa T., Bar M., Becker G., Jovanovic V.M., Zega K., Binder E.B., Brodski C. Abnormal development of monoaminergic neurons is implicated in mood fluctuations and bipolar disorder. Neuropsychopharmacology 2015, 40:839-848.
20. Jung S.H., Park J.M., Moon E., Chung Y.I., Lee B.D., Lee Y.M., Kim J.H., Kim S.Y., Jeong H.J. Delay in the recovery of normal sleep-wake cycle after disruption of the light-dark cycle in mice: a bipolar disorder-prone animal model. Psychiatry Investig. 2014, 11:487-491.
21. Kang K., Kim Y.J., Kim Y.H., Roh J.N., Nam J.M., Kim P.Y., Ryu W.S., Lee S.H., Yoon B.W. Lithium pretreatment reduces brain injury after intracerebral hemorrhage in rats. Neurol. Res. 2012, 34:447-454.
22. Kathleen Holmes M., Bearden C.E., Barguil M., Fonseca M., Serap Monkul E., Nery F.G., Soares J.C., Mintz J., Glahn D.C. Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord. 2009, 11:33-40.
23. Le-Niculescu H., et al. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:134-166.
24. Lopes-Borges J., Valvassori S.S., Varela R.B., Tonin P.T., Vieira J.S., Gonçalves C.L., Streck E.L., Quevedo J. Histone deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic metabolic alterations induced by ouabain. Pharmacol. Biochem. Behav. 2015, 128:89-95.
25. Macriỳ S., Adriani W., Chiarotti F., Laviola G. Risk taking during exploration of a plus-maze is greater in adolescent than in juvenile or adult mice. Anim. Behav. 2002, 64:541-546.
26. Mikics E., Barsy B., Barsvári B., Haller J. Behavioral specificity of non-genomic glucocorticoid effects in rats: effects on risk assessment in the elevated plus-maze and the open-field. Horm. Behav. 2005, 48:152-162.
27. Miró X., Meier S., Dreisow M.L., Frank J., Strohmaier J., Breuer R., Schmäl C., Albayram Ö., Pardo-Olmedilla M.T., Mühleisen T.W., Degenhardt F.A., Mattheisen M., Reinhard I., Bilkei-Gorzo A., Cichon S., Seidenbecher C., Rietschel M., Nöthen M.M., Zimmer A. Studies in humans and mice implicate neurocan in the etiology of mania. Am. J. Psychiatry 2012, 169:982-990.
28. Mizuta T., Segawa T. Chronic effects of imipramine and lithium on postsynaptic 5-HT1A and 5-HT1B sites and on presynaptic 5-HT3 sites in rat brain. Jpn. J. Pharmacol. 1988, 47:107-113.
29. Ohmura Y., Tsutsui-Kimura I., Kumamoto H., Minami M., Izumi T., Yamaguchi T., Yoshida T., Yoshioka M. Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. Psychopharmacology (Berl.) 2012, 219:421-432.
30. Palm S., Momeni S., Lundberg S., Nylander I., Roman E. Risk-assessment and risk-taking behavior predict potassium- and amphetamine-induced dopamine response in the dorsal striatum of rats. Front. Behav. Neurosci. 2014, 8:236.
31. Pathak G., Ibrahim B.A., McCarthy S.A., Baker K., Kelly M.P. Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures. Neuropharmacology 2015, 95:434-447.
32. Pezzato F.A., Can A., Hoshino K., de Horta J.A., Mijares M.G., Gould T.D. Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus. Psychopharmacology (Berl.) 2015, 232:1441-1450.
33. Shaltiel G., Maeng S., Malkesman O., Pearson B., Schloesser R.J., Tragon T., Rogawski M., Gasior M., Luckenbaugh D., Chen G., Manji H.K. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry 2008, 13:858-872.
34. Steckert A.V., Valvassori S.S., Varela R.B., Mina F., Resende W.R., Bavaresco D.V., Ornell F., Dal-Pizzol F., Quevedo J. Effects of sodium butyrate on oxidative stress and behavioral changes induced by administration of D-AMPH. Neurochem. Int. 2013, 62:425-432.
35. Storlien L.H., Higson F.M., Gleeson R.M., Smythe G.A., Atrens D.M. Effects of chronic lithium, amitriptyline and mianserin on glucoregulation, corticosterone and energy balance in the rat. Pharmacol. Biochem. Behav. 1985, 22:119-125.
36. Tan H., Young L.T., Shao L., Che Y., Honer W.G., Wang J.F. Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. Int. J. Neuropsychopharmacol. 2012, 15:1275-1285.
37. Valvassori S.S., Rezin G.T., Ferreira C.L., Moretti M., Goncalves C.L., Cardoso M.R., Streck E.L., Kapczinsky F., Quevedo J. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J. Psychiatric Res. 2010, 44:903-909.